CHMA:NSD-Chiasma, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.01

Change

-0.01 (-0.33)%

Market Cap

USD 0.18B

Volume

0.53M

Average Target Price

USD 13.50 (+348.50%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.07 (+1.46%)

USD54.66B 20.44 15.09
MRNA Moderna, Inc

+7.04 (+5.26%)

USD53.62B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

-1.19 (-0.25%)

USD51.03B 15.61 12.36
ALXN Alexion Pharmaceuticals, Inc

+0.54 (+0.35%)

USD33.96B 56.79 33.32
BGNE BeiGene, Ltd

-6.35 (-2.02%)

USD29.36B N/A N/A
BNTX BioNTech SE

+7.65 (+6.68%)

USD27.29B -99,999.99 N/A
SGEN Seagen Inc

-1.62 (-1.12%)

USD26.58B 43.50 36.12
RPRX Royalty Pharma plc

+0.37 (+0.88%)

USD25.46B 22.60 15.46
GMAB Genmab A/S

+0.58 (+1.73%)

USD21.63B 26.59 3.09
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CHMA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.80% 10% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.80% 10% F 5% F
Trailing 12 Months  
Capital Gain -24.56% 15% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.56% 15% F 5% F
Trailing 5 Years  
Capital Gain -76.34% 22% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -76.34% 22% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain 43.06% 73% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.06% 73% C 85% B
Risk Return Profile  
Volatility (Standard Deviation) 109.41% 23% F 12% F
Risk Adjusted Return 39.36% 65% D 62% D-
Market Capitalization 0.18B 30% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.87 90% A- 69% D+
Price / Cash Flow Ratio -2.33 17% F 61% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -84.23% 33% F 14% F
Return on Invested Capital -78.56% 27% F 10% F
Return on Assets -32.09% 37% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.63 65% D 58% F
Short Percent 5.64% 53% F 35% F
Beta 1.38 49% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector